On September 29, GENFLEET-B rose 7.59% in regular trading, reaching HK$29.48 with turnover of approximately HK$27.11 million, recovering sharply from the prior session's 8.83% decline.

On the news front, the company continued its share repurchase program, buying back 116,000 shares on September 28 for approximately HK$3.19 million at prices between HK$26.98 and HK$27.96 per share. The company has now conducted 10 buybacks this year, accumulating 988,000 repurchased shares totaling approximately HK$25.58 million, signaling management's confidence in the company's intrinsic value.

Multiple positive catalysts have converged in recent weeks. The company's lead asset GFH375 in combination with cetuximab was proposed for inclusion on China's Breakthrough Therapy Designation list for KRAS G12D-mutant metastatic colorectal cancer on September 18. Additionally, updated Phase 2 data for GFH375 monotherapy in pretreated KRAS G12D-mutant NSCLC presented at the World Conference on Lung Cancer showed an objective response rate of 59.2% and a 12-month overall survival rate of 77%. Both BOCOM International and CITIC Securities maintained Buy ratings, citing a rich pipeline of clinical catalysts ahead.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)